Compare Heron Therapeutics Inc (HRTX) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Paychex, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while Paychex, Inc. trades at $121.38 (market cap $43.14B). The key difference: Paychex, Inc. is far larger — about 701.8× Heron Therapeutics Inc's market cap, and Paychex, Inc. pays a 3.92% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | PAYX | |
|---|---|---|
Market Cap | $61.47M | $43.14B |
Sector | Health | Industrials |
52-Week High | $1.49 | $140.81 |
52-Week Low | $0.32 | $85.57 |
Enterprise Value | $168.21M | $46.63B |
Dividend Yield | — | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.
Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.
Paychex (PAYX) trades at $120.34, down 0.69% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a 27.03% net income margin and consistent earnings beats, though valuation ratios like a P/E of 24.81 are elevated. Recent news highlights steady small business employment data and product expansion, supporting its core HR services business.
The outlook is mixed: solid fundamentals and dividend payments offer stability, but high valuation and analyst caution (63.33% hold rating) suggest limited near-term upside. Risks include economic sensitivity and debt levels, yet long-term growth in HR outsourcing remains a tailwind for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
